CA2128699A1 - Utilisation de derives 3-arylindole et 3-arylindazole pour le traitement des psychoses - Google Patents

Utilisation de derives 3-arylindole et 3-arylindazole pour le traitement des psychoses

Info

Publication number
CA2128699A1
CA2128699A1 CA002128699A CA2128699A CA2128699A1 CA 2128699 A1 CA2128699 A1 CA 2128699A1 CA 002128699 A CA002128699 A CA 002128699A CA 2128699 A CA2128699 A CA 2128699A CA 2128699 A1 CA2128699 A1 CA 2128699A1
Authority
CA
Canada
Prior art keywords
alkyl
cycloalkyl
optionally substituted
trifluoromethyl
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002128699A
Other languages
English (en)
Inventor
Kim Andersen
Torben Skarsfeldt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2128699A1 publication Critical patent/CA2128699A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
CA002128699A 1992-01-23 1993-01-22 Utilisation de derives 3-arylindole et 3-arylindazole pour le traitement des psychoses Abandoned CA2128699A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK9284A DK8492D0 (da) 1992-01-23 1992-01-23 Behandling af psykoser
DK0084/92 1992-01-23

Publications (1)

Publication Number Publication Date
CA2128699A1 true CA2128699A1 (fr) 1993-08-05

Family

ID=8089556

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002128699A Abandoned CA2128699A1 (fr) 1992-01-23 1993-01-22 Utilisation de derives 3-arylindole et 3-arylindazole pour le traitement des psychoses

Country Status (11)

Country Link
EP (1) EP0621781A1 (fr)
JP (1) JPH07503240A (fr)
AU (1) AU670063B2 (fr)
CA (1) CA2128699A1 (fr)
CZ (1) CZ176494A3 (fr)
DK (1) DK8492D0 (fr)
NO (1) NO942686D0 (fr)
RU (1) RU94035658A (fr)
SK (1) SK86394A3 (fr)
WO (1) WO1993014758A1 (fr)
ZA (1) ZA93491B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK206591D0 (da) * 1991-12-23 1991-12-23 Lundbeck & Co As H Behandling af psykoser
WO1998054168A1 (fr) * 1997-05-30 1998-12-03 Banyu Pharmaceutical Co., Ltd. Derives de 2-0xoimidazole
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
DK181190D0 (da) * 1990-07-30 1990-07-30 Lundbeck & Co As H 3-aryl-indol- eller 3-aryl-indazolderivater

Also Published As

Publication number Publication date
JPH07503240A (ja) 1995-04-06
WO1993014758A1 (fr) 1993-08-05
EP0621781A1 (fr) 1994-11-02
DK8492D0 (da) 1992-01-23
NO942686L (no) 1994-07-18
AU670063B2 (en) 1996-07-04
RU94035658A (ru) 1996-06-20
CZ176494A3 (en) 1995-04-12
NO942686D0 (no) 1994-07-18
ZA93491B (en) 1993-08-23
SK86394A3 (en) 1995-04-12
AU3449493A (en) 1993-09-01

Similar Documents

Publication Publication Date Title
US5112838A (en) Method of treating psychoses in human beings with the atypical neuroleptic 5-chloro-1-(4-fluorophenyl)-3-(1-(2-(2-imidazolidinon-1-yl)ethyl-4-piperidyl)1h-indole
US5238945A (en) Method of treating psychoses
PL201685B1 (pl) Zastosowanie N-piperydyno-5-(4-chlorofenylo)-1-(2,4-dichlorofenylo)-4-metylopirazolo-3-karboksyamidu do wytwarzania leków
CA2167004C (fr) Agent pour le traitement de troubles mentaux associes a des troubles cerebrovasculaires
AU764304B2 (en) Use of saredutant and of its pharmaceutically acceptable salts for the preparation of medicinal products that are useful in the treatment or prevention of major depressive disorders
EP1123702A1 (fr) Analgesiques
WO1992014464A1 (fr) Utilisation d'antagonistes de recepteurs sigma dans le traitement de la cocainomanie
JPH08503449A (ja) 物質濫用疾患治療剤
CA2128699A1 (fr) Utilisation de derives 3-arylindole et 3-arylindazole pour le traitement des psychoses
AU668537B2 (en) Use of arylindole derivatives for the treatment of psychoses
US6841557B2 (en) Compounds for the treatment of addictive disorders
KR20010099648A (ko) 신규 조성물
GB2362826A (en) A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist
JP2000007568A (ja) 神経栄養因子様作用剤
JP2002532548A (ja) いびきおよび解剖学的上気道の高抵抗症候群を治療するための薬剤を製造するための５ｈｔ２ａおよび５ｈｔ２ａ／ｃ受容体アンタゴニストの使用

Legal Events

Date Code Title Description
FZDE Discontinued